Skip to main content

NextCure, Inc. (NXTC)

NASDAQ: NXTC · IEX Real-Time Price · USD
6.98
-0.07 (-0.99%)
After-hours:Sep 24, 2021 4:06 PM EDT
7.05
0.16 (2.32%)
At close: Sep 24, 4:00 PM
Market Cap194.66M
Revenue (ttm)n/a
Net Income (ttm)-66.35M
Shares Out27.61M
EPS (ttm)-2.41
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume155,288
Open6.85
Previous Close6.89
Day's Range6.80 - 7.10
52-Week Range6.70 - 14.40
Beta-0.51
AnalystsBuy
Price Target17.57 (+149.2%)
Est. Earnings DateNov 4, 2021

About NXTC

NextCure, Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. Its lead product candidate is NC318, which is in Phase II clinical trials for the treatment of advanced or metastatic solid tumors. The company is also developing NC410, which is in Phase I for novel immunomedicine designed to block immune suppression mediated by an immune modulator called Leukocyte-Associated Immunoglobulin-like Receptor 1;...

IndustryBiotechnology
IPO DateMay 9, 2019
CEOMichael Richman
Employees90
Stock ExchangeNASDAQ
Ticker SymbolNXTC
Full Company Profile

Financial Performance

In 2020, NextCure's revenue was $22.38 million, an increase of 252.58% compared to the previous year's $6.35 million. Losses were -$36.60 million, 8.50% more than in 2019.

Financial Statements

Analyst Forecast

According to 9 analysts, the average rating for NextCure stock is "Buy." The 12-month stock price forecast is 17.57, which is an increase of 149.22% from the latest price.

Price Target
$17.57
(149.22% upside)
Analyst Consensus: Buy

News

NextCure to Present at the H.C. Wainwright 23rd Annual Global Investment Conference

BELTSVILLE, Md., Sept. 07, 2021 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicine...

2 weeks ago - GlobeNewsWire

NextCure to Present at the 19th Annual Morgan Stanley Global Healthcare Conference

BELTSVILLE, Md., Sept. 02, 2021 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicine...

3 weeks ago - GlobeNewsWire

NextCure Launches Early-Stage Study For NC762 In Solid Tumor Settings

NextCure Inc (NASDAQ: NXTC) has initiated the clinical trial of its third product candidate, NC762, a humanized B7-H4 monoclonal antibody. The Phase 1 dose-escalation portion of this Phase 1/2 open-labe...

2 months ago - Benzinga

NextCure Initiates Phase 1/2 Clinical Trial of NC762 for Solid Tumors

BELTSVILLE, Md., July 06, 2021 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company discovering and developing novel, first-in-class immunomedicines to treat can...

2 months ago - GlobeNewsWire

NextCure's Immunomedicine NC410 Shows Promising Anti-Cancer Activity In Preclinical Studies

NextCure Inc (NASDAQ: NXTC) has published preclinical data for NC410 in the online journal eLife. NC410 is currently being evaluated in a Phase 1/2 trial in patients with advanced or metastatic solid tu...

3 months ago - Benzinga

NextCure and Collaborators Publish Preclinical Data on Novel Immunomedicine NC410

BELTSVILLE, Md., June 21, 2021 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company discovering and developing novel, first-in-class immunomedicines to treat can...

3 months ago - GlobeNewsWire

NextCure to Present at the JMP Securities Life Sciences Conference

BELTSVILLE, Md., June 10, 2021 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines...

3 months ago - GlobeNewsWire

NextCure to Present Trials in Progress Poster for NC410 at the 2021 American Society of Clinical Oncology (ASCO) Annu...

BELTSVILLE, Md., May 19, 2021 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines ...

4 months ago - GlobeNewsWire

NextCure Reports First Quarter 2021 Financial Results

BELTSVILLE, Md., May 06, 2021 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines ...

4 months ago - GlobeNewsWire

NextCure to Present at the BofA Securities 2021 Virtual Health Care Conference

BELTSVILLE, Md., May 05, 2021 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines ...

4 months ago - GlobeNewsWire

NextCure to Present at the 7th Annual Truist Securities Life Sciences Summit

BELTSVILLE, Md., April 28, 2021 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicine...

4 months ago - GlobeNewsWire

A Trio of Net Current Asset Value Stock Picks

Other symbols:HAPP
5 months ago - GuruFocus

NextCure Presents Preclinical Data for NC762 at American Association for Cancer Research (AACR) Annual Meeting 2021

BELTSVILLE, Md., April 10, 2021 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicine...

5 months ago - GlobeNewsWire

NextCure to Present at the 20th Annual Needham Virtual Healthcare Conference

BELTSVILLE, Md., April 07, 2021 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicine...

5 months ago - GlobeNewsWire

NextCure Provides Business Update and Reports Fourth Quarter and Full Year 2020 Financial Results

BELTSVILLE, Md., March 04, 2021 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicine...

6 months ago - GlobeNewsWire

REMINDER: NextCure to Host Virtual R&D Update Event on March 4, 2021

BELTSVILLE, Md., March 02, 2021 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicine...

6 months ago - GlobeNewsWire

NextCure to Host Virtual R&D Update Event on March 4, 2021

BELTSVILLE, Md., Feb. 26, 2021 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines...

6 months ago - GlobeNewsWire

LONG-TERM INVESTOR ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against NextCure, Inc. a...

Los Angeles, California--(Newsfile Corp. - February 11, 2021) -  The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against NextCure, Inc....

7 months ago - Newsfile Corp

LONG-TERM SHAREHOLDER REMINDER: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against NextCure, ...

LOS ANGELES--(BUSINESS WIRE)---- $NXTC #NXTC--LONG-TERM SHAREHOLDER REMINDER: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against NextCure, Inc.

7 months ago - Business Wire

Dr. Han Myint Appointed as NextCure's Chief Medical Officer

BELTSVILLE, Md., Jan. 14, 2021 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines...

8 months ago - GlobeNewsWire

The 10 Worst Performing Stocks of 2020

These companies are eager to say good riddance to the year that was.

8 months ago - The Motley Fool

LONG-TERM SHAREHOLDER ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against NextCure, Inc...

LOS ANGELES--(BUSINESS WIRE)---- $NXTC #NXTC--The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against NextCure, Inc. (“NextCure” or “th...

9 months ago - Business Wire

NextCure Provides Updates on NC318 Clinical Program

BELTSVILLE, Md., Dec. 17, 2020 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines...

9 months ago - GlobeNewsWire

NextCure (NXTC) in Focus: Stock Moves 7.6% Higher

NextCure (NXTC) saw a big move last session, as its shares jumped nearly 8% on the day, amid huge volumes.

9 months ago - Zacks Investment Research

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of NextCure, Inc. - NXTC

NEW YORK, Nov. 26, 2020 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of NextCure (“NextCure” or the “Company”) (NASDAQ: NXTC).   Such investors are advised to contact...

9 months ago - GlobeNewsWire